Malkinson John P, Zloh Mire, Kadom Mohanad, Errington Rachel, Smith Paul J, Searcey Mark
Department of Pharmaceutical and Biological Chemistry, School of Pharmacy, University of London, 29-39 Brunswick Square, London WC1N 1AX, UK.
Org Lett. 2003 Dec 25;5(26):5051-4. doi: 10.1021/ol0360849.
The first solid-phase synthesis of the chlorofusin peptide is described. The synthesis involved side-chain immobilization of N(alpha)-Fmoc-Asp-ODmab. Synthesis of the linear peptide, initially incorporating racemic Ade8 and unsubstituted ornithine in place of the chromophore-bearing residue, was followed by cyclization on resin and peptide release to give a mixture of diastereomers. Resynthesis identified (by HPLC) the second isomer as analogous to the natural product. Initial biological assays, using an immunofluorescence method, suggest that the compounds are not cytotoxic but do not inhibit the p53/mdm2 interaction. [structure: see text]
描述了氯富辛肽的首次固相合成。该合成涉及N(α)-Fmoc-Asp-ODmab的侧链固定。线性肽的合成最初引入外消旋的Ade8和未取代的鸟氨酸以替代带有发色团的残基,随后在树脂上进行环化并释放肽,得到非对映异构体混合物。重新合成(通过高效液相色谱法)鉴定出第二种异构体类似于天然产物。使用免疫荧光法进行的初步生物学测定表明,这些化合物没有细胞毒性,但不抑制p53/mdm2相互作用。[结构:见正文]